Introducing minimal residual disease in acute myeloid leukemia.

  title={Introducing minimal residual disease in acute myeloid leukemia.},
  author={Yishai Ofran and Jacob M. Rowe},
  journal={Current opinion in hematology},
  volume={22 2},
PURPOSE OF REVIEW Acute myeloid leukemia (AML) is a heterogeneous disease. Detection of minimal residual disease (MRD) has the potential to improve risk stratification, and its routine monitoring may allow timely therapeutic actions such as allogeneic hematopoietic stem cell transplantation. The current review will discuss challenges and available evidence for clinical application of MRD detection in AML management. RECENT FINDINGS The heterogeneous nature of AML, variations in genetic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS